Stanford study prevents pancreatic tumor growth in mice by inhibiting key protein

February 02, 2009

STANFORD, Calif. - Researchers at Stanford University School of Medicine have identified a protein critical for the growth of pancreatic cancer. Blocking the expression of the protein slowed or prevented tumor growth in mice and made cultured cancer cells vulnerable to the conditions of low oxygen that occur in solid tumors.

"This research clearly shows that inhibiting the protein inhibits the tumor's ability to grow," said cancer biologist Amato Giaccia, PhD. "Ultimately, we'd like to be able to specifically knock out the expression of this protein in pancreatic tumors in humans."

Pancreatic cancer is a highly aggressive and deadly disease that accounts for more than 30,000 deaths in the United States annually, and current therapies are largely ineffective.

"Right now, we have very little to offer these patients," said Giaccia. He is the Jack, Lulu and Sam Willson Professor and professor of radiation oncology and the senior author of the research, which will be published Feb. 1 in the journal Cancer Research. Giaccia is also a member of the Stanford Cancer Center.

The researchers studied a protein called connective tissue growth factor, or CTGF. Also known as CCN2, the protein is involved in the abnormal growth of connective tissue in response to injury or disease. It was also thought to be involved in pancreatic tumor progression, although the exact role it played was unknown.

Giaccia and his collaborators found that human pancreatic cancer cells expressing high levels of CCN2 grew robustly when injected under the skin of mice. In fact, in the developing tumor these cells soon out-competed others that expressed lower levels of the protein. Conversely, pancreatic cancer cells in which CCN2 expression was suppressed were either less likely or unable to form tumors when injected into mice.

The researchers observed similar effects when the cancer cells were injected directly into the animals' pancreases. Cancer cells expressing high levels of CCN2 formed tumors that grew more rapidly and metastasized more aggressively than did those expressing lower levels, and the mice died sooner than others injected with cancer cells expressing less CCN2.

It's difficult for many types of rapidly growing solid tumors to recruit and build enough blood vessels to keep all the cancer cells adequately oxygenated. Normal cells undergo a process of programmed cell death when oxygen levels drop too far. Overcoming this response to low oxygen levels - a condition called hypoxia - is a critical step in tumor progression.

The researchers wondered if CCN2 played a role in keeping tumor cells alive in hypoxic conditions. If so, this might explain why CCN2-expressing cancer cells are favored during tumor growth. They found that blocking CCN2 expression in cultured pancreatic cancer cells made them significantly more sensitive to hypoxia-induced death than their peers. Additionally, CCN2 was more highly expressed in pancreatic tumor samples from human patients than in neighboring tissue and CCN2 expression seemed to correlate with the expression of another protein expressed by hypoxic cells. Finally, hypoxic conditions themselves cause the pancreatic cancer cells to make CCN2.

Many other cellular conditions can also kick-start CCN2 expression, including the presence of CCN2 itself. The activation of other pathways known to be involved in cancer also increases its expression. As a result, many of the events that occur in a developing tumor act as a kind of perfect storm to support the production of ever-larger amounts of CCN2, which then support additional tumor growth and metastasis.

Looking ahead, the researchers would like to know whether people with pancreatic cancer could benefit from therapies targeting CCN2. A phase-1 clinical trial testing the safety of an antibody that binds CCN2 and blocks its activity in a small number of patients began in December at Stanford and Dartmouth-Hitchcock Medical Center. Phase-1 clinical trials are not designed to determine whether a treatment works - only whether it is safe enough for further testing. Albert Koong, MD, PhD, an assistant professor of radiation oncology and a member of the Cancer Center, is the principal investigator for the Stanford arm of the trial.

"We saw a pronounced effect of CCN2 inhibition in these experiments in mice," said Giaccia. "Our hope is that one day a combination of standard therapy and antibody treatment will have an effect on tumor progression in human patients."

Stanford University Medical Center

---

---

	Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series) by Douglas B. Evans (Editor), Peter W.T. Pisters (Editor), James L. Abruzzese (Editor) The MD Anderson Solid Tumor Oncology series presents cutting-edge surgical treatment and medical therapy for specific sites. This volume, Pancreatic Cancer, addresses epidemiology and molecular biology, inherited syndromes, staging, surgical techniques, multimodality therapy, and emerging therapies. The individual chapters focus on narrow, specific topics to produce a reference work of value to those interested in pancreatic cancer from a clinical and translational research perspective. A must-have for surgical oncologists and general surgeons.
	Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series) by Andrew M. Lowy (Editor), Steven D. Leach (Editor), Philip Philip (Editor) Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. This book provides information on the recent progress and improvements. It brings to the forefront the most current advances that have been made in understanding pancreatic cancer development and successfully treating this disease.
	The influences of pancreatic tumors on the stomach, by Robert M Zollinger (Author)
	Atlas of Exocrine Pancreatic Tumors: Morphology, Biology, and Diagnosis with an International Guide for Tumor Classification by Parviz M. Pour (Editor), Yoichi Konishi (Editor), Günter Klöppel (Editor), Daniel S. Longnecker (Editor) This atlas consists of an interdisciplinary survey of all aspects of exocrine pancreatic cancer, including gross and microscopic appearance, differential diagnosis, and the immunological and molecular biological characteristics of pancreatic tumors. In addition to investigating the relationship between tumor morphology and molecular biology, clinical observations, and prognosis, this book offers pointers on the use of modern biotechnology in histopathological research. Since major sections of the studies compiled in this volume cover new ground, it will serve as an invaluable reference work for researchers, clinical practitioners, and students in the fields of gastroenterology, oncology, and histopathology.
	Pancreatic Tumors in Children (Cancer Treatment and Research) by G. Bennett Humphrey (Editor), Gerald B. Grindey (Editor), Louis P. Dehner (Editor), Ronald T. Acton (Editor), Theodore J. Pysher (Editor)
	Surgery of Pancreatic Tumors by Alexande Brunschwig (Author)
	Pancreatic Cancer: A Patient and His Doctor Balance Hope and Truth (A Johns Hopkins Press Health Book) by Michael J. Lippe (Author), Dung T. Le (Author) Michael J. Lippe was diagnosed with pancreatic cancer in 2007. This is his story, and the story of pancreatic cancer, narrated by Lippe and Dr. Dung T. Le, the physician who is treating him.In telling these stories, Lippe and Le alternate chapters. Lippe writes about the early signs that something was wrong; Le continues with a description of pancreatic cancer, its symptoms, and its treatments. Lippe talks about his prognosis, contemplates the prospect of death, and describes how he began to cope; Le explains the importance, for both doctor and patient, of balancing hope and truth. Lippe speaks frankly about the toll the disease takes on his marriage and family; Le offers a general picture of what most patients can expect with their illness. The book concludes with Lippe and Le’s...
	Pancreatic tumors in patients with lung malignancies: a spectrum of clinicopathologic considerations.(Original Article): An article from: Southern Medical Journal by Roderich E. Schwarz (Author), Peiguo G. Chu (Author), Frederic W., Jr. Grannis (Author) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on September 1, 2004. The length of the article is 3857 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Pancreatic tumors in patients with lung malignancies: a spectrum of clinicopathologic considerations.(Original Article) Author: Roderich E. Schwarz Publication: Southern Medical Journal (Refereed) Date: September 1, 2004 Publisher: Southern Medical Association Volume: 97 Issue: 9 Page: 811(5) Distributed by Thomson...
	Rad-16. Percutaneous MRI guided and monitored cryosurgery of pancreatic tumors.(Section on Radiology): An article from: Southern Medical Journal by Patrick E., Jr. Sewell (Author) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on October 1, 2004. The length of the article is 1267 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Rad-16. Percutaneous MRI guided and monitored cryosurgery of pancreatic tumors.(Section on Radiology) Author: Patrick E., Jr. Sewell Publication: Southern Medical Journal (Refereed) Date: October 1, 2004 Publisher: Southern Medical Association Volume: 97 Issue: 10 Page: S69(1) Distributed by Thomson...
	PAT7 Multicentric granular cell tumor with unusual mammary, gastric and pancreatic involvement: A case presentation.(Brief Article): An article from: Southern Medical Journal by Southern Medical Association (Publisher) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on December 1, 2001. The length of the article is 455 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: PAT7 Multicentric granular cell tumor with unusual mammary, gastric and pancreatic involvement: A case presentation.(Brief Article) Publication: Southern Medical Journal (Refereed) Date: December 1, 2001 Publisher: Southern Medical Association Volume: 94 Issue: 12 Page: S24(1) Article Type: Brief Article Distributed by Thomson...